病例报告:转移性耐火不分化的小圆细胞肉瘤成功用surufatinib和camrelizumab治疗
Yong Li1,2,3, Jinpeng Huang1,2,3, Xian Chen1,2
1Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Frontiers in oncology
|July 26, 2024
概括
不分化的小圆细胞肉瘤 (uSRCSs) 具有挑战性治疗. 一名患有晚期USRCS的患者在多次先前治疗失败后对surufatinib和camrelizumab产生了积极反应,实现了26个月的无进展生存期.
科学领域:
- 在瘤学瘤学.
- 医学遗传学 医学遗传学
- 药理学 药理学是指药理学的学科.
背景情况:
- 不分化的小圆细胞肉瘤 (uSRCSs) 存在诊断和治疗方面的挑战.
- 目前对高级USRCS的治疗依赖于一般的肉瘤协议,缺乏特定的向疗法.
- uSRCSs的遗传景观异质,有些病例缺乏可识别的驱动突变.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
